LCTX
Lineage Cell Therapeutics Inc
3월 13일 4:00 PM ET (한국 3/14 05:00)
$1.61
+0.03 ▲ +1.90%
🌙 3월 13일 7:56 PM ET (한국 3/14 08:56)
$1.61
+0.00 +0.00%
| Index | - | P/E | - | EPS (ttm) | -0.28 | Insider Own | 5.53% | Shs Outstand | 0.24B | Perf Week | -12.97% |
| Market Cap | 0.40B | Forward P/E | - | EPS next Y | -163.63% | Insider Trans | 0.11% | Shs Float | 0.24B | Perf Month | -10.56% |
| Enterprise Value | 0.35B | PEG | - | EPS next Q | -0.01 | Inst Own | 40.98% | Short Float | 10.65% | Perf Quarter | -7.47% |
| Income | -0.06B | P/S | 27.54 | EPS this Y | 86.9% | Inst Trans | 3.56% | Short Ratio | 20.83 | Perf Half Y | 24.81% |
| Sales | 0.01B | P/B | 8.79 | EPS next 5Y | - | ROA | -56.27% | Short Interest | 25.05M | Perf YTD | -3.59% |
| Book/sh | 0.18 | P/C | 7.19 | EPS past 3/5Y | -21.3% -14.94% | ROE | -103.36% | 52W High | -22.97% ($2.09) | Perf Year | 209.62% |
| Cash/sh | 0.22 | P/FCF | - | Sales past 3/5Y | -0.33% 79.88% | ROIC | -137.77% | 52W Low | 340.98% ($0.37) | Perf 3Y | 13.38% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -186.42% | Gross Margin | 94.19% | Volatility(W/M) | 7.16% 6.31% | Perf 5Y | -35.08% |
| Dividend TTM | - | EV/Sales | 23.8 | Sales Y/Y TTM | 53.24% | Oper. Margin | -149.62% | ATR (14) | 0.11 | Perf 10Y | -19.81% |
| Dividend Ex-Date | - | Quick Ratio | 5.2 | EPS Q/Q | 123.65% | Profit Margin | -436.47% | RSI (14) | 40.35 | Recom | 1.43 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.2 | Sales Q/Q | 130.4% | SMA20 | -10.43% ($1.8) | Beta | 1.8 | Target Price | $4.33 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 3000000 | SMA50 | -6.7% ($1.73) | Rel Volume | 1.16 | Prev Close | $1.58 |
| Employees | 77 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | 109.32% 235.59% | SMA200 | 11.17% ($1.45) | Avg Volume(3M) | 1.20M | Price | $1.61 |
| IPO | 1992/3/5 | Option/Short | Yes/Yes | Trades | 4526 | Volume | 1,398,742 | Change | 1.9% |
뉴스 로딩 중...